UK-CAB 30 – Testing

Friday 31 July 2009

Testing

At the MRC Clinical Trials Unit, 222 Euston Road, London, NW1

Programme

09:30 – 10:00 Registration, refreshments and expenses
10:00 – 10:15 Welcome and UKCAB updates – Michael Marr
10:15 –  11:00 BHIVA Routine Monitoring Guidelines – Matt Williams
11:00 – 11:15 Break
11:15 – 12:15 HIV Treatment Advocacy Overview

  • Definitions of advocacy – Michael Marr
  • History of advocacy film highlights
  • Advocacy Training in Practice – Winnie Sseruma
12.15 – 12.30 Pre-Meeting for BMS – Simon Collins
12:30 – 14:00 Lunch
14:00 – 15:15 Company meeting: BMS
15:15 – 15:30 Break
15:30 – 16:00 Conference Feedback & UKCAB AOB – Simon Collins
16:00 Close

Background Reading

Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment.
Download as a PDF file [416 Kb]

Denver Principles
http://en.wikipedia.org/wiki/People_With_AIDS#The_Denver_Principles

The Early AIDS Epidemic in the US: Views from Atlanta and Hollywood Harold Jaffe Univ of Oxford, UK
http://www.retroconference.org/2008/data/files/retro2008_frameset.html

Scottish Independent Advocacy Alliance
http://www.siaa.org.uk/images/stories/siaaprinciples%26standardsforweb.pdf

http://www.ncbi.nlm.nih.gov/pubmed/19496633?log$=activity

http://www.hivinsite.com/insite?page=hmq-0810-04

http://www.avert.org/aids-history-86.htm

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.

Edit
Published: July 31, 2009
Last edited: August 13, 2013